# Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

> **NCT02015780** · PHASE3 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Type 2 Diabetes Mellitus
- Chronic Kidney Disease

## Interventions

- **DRUG:** Fasiglifam
- **DRUG:** Placebo
- **DRUG:** Antihyperglycemic therapy

## Key facts

- **NCT ID:** NCT02015780
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to potential concerns about liver safety (See Detailed Description)
- **Last updated:** 2014-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015780, "Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02015780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*